SLDB

Solid Biosciences Inc. is a pioneering life sciences firm headquartered in Cambridge, Massachusetts, dedicated to advancing gene therapies specifically for Duchenne muscular dystrophy (DMD), a severe genetic disorder primarily affecting young boys. The company is focused on creating innovative solutions to meet significant unmet medical needs, particularly through its promising pipeline aimed at restoring functional dystrophin. By emphasizing translational science and engaging in strategic collaborations within the DMD community, Solid Biosciences is committed to improving the quality of life for individuals affected by this condition and transforming therapeutic approaches in the realm of rare genetic diseases.